TERNS PHARMACEUTICALS INC (TERN) Stock Price, Quote, News and Overview
NASDAQ:TERN - Nasdaq - US8808811074 - Common Stock - Currency: USD
TERN Quote, Performance and Key Statistics
3.11
+0.01 (+0.32%)
The current stock price of TERN is 3.11 USD. In the past month the price decreased by -12.64%. In the past year, price decreased by -48.25%.
TERN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 53.61 | 699.12B | ||
| JNJ | JOHNSON & JOHNSON | 15.44 | 373.45B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.08 | 317.70B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.93 | 228.64B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.55 | 225.80B | ||
| MRK | MERCK & CO. INC. | 9.86 | 192.95B | ||
| PFE | PFIZER INC | 7.32 | 133.55B | ||
| SNY | SANOFI-ADR | 11.22 | 120.15B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.58 | 98.25B | ||
| GSK | GSK PLC-SPON ADR | 9.26 | 83.26B | ||
| ZTS | ZOETIS INC | 28.01 | 75.08B | ||
| HLN | HALEON PLC-ADR | 23.16 | 51.11B |
Related stock screener links
About TERN
Company Profile
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 59 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). The company is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Company Info
TERNS PHARMACEUTICALS INC
1065 East Hillsdale Blvd., Suite 100, Suite 100
Foster City CALIFORNIA 94404 US
CEO: Senthil Sundaram
Employees: 66
Phone: 16505255535
TERNS PHARMACEUTICALS INC / TERN FAQ
What is the stock price of TERNS PHARMACEUTICALS INC today?
The current stock price of TERN is 3.11 USD. The price increased by 0.32% in the last trading session.
What is the ticker symbol for TERNS PHARMACEUTICALS INC stock?
The exchange symbol of TERNS PHARMACEUTICALS INC is TERN and it is listed on the Nasdaq exchange.
On which exchange is TERN stock listed?
TERN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TERNS PHARMACEUTICALS INC stock?
16 analysts have analysed TERN and the average price target is 20.18 USD. This implies a price increase of 548.92% is expected in the next year compared to the current price of 3.11. Check the TERNS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TERNS PHARMACEUTICALS INC worth?
TERNS PHARMACEUTICALS INC (TERN) has a market capitalization of 271.63M USD. This makes TERN a Micro Cap stock.
How many employees does TERNS PHARMACEUTICALS INC have?
TERNS PHARMACEUTICALS INC (TERN) currently has 66 employees.
What are the support and resistance levels for TERNS PHARMACEUTICALS INC (TERN) stock?
TERNS PHARMACEUTICALS INC (TERN) has a support level at 2.77 and a resistance level at 3.11. Check the full technical report for a detailed analysis of TERN support and resistance levels.
Should I buy TERNS PHARMACEUTICALS INC (TERN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TERN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TERN, evaluating the profitability, health, valuation and growth aspects
- TERNS PHARMACEUTICALS INC (TERN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TERNS PHARMACEUTICALS INC (TERN) Sales and EPS estimates to see what analysts future expectations are.
- TERNS PHARMACEUTICALS INC (TERN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TERNS PHARMACEUTICALS INC (TERN) Insider and Institutional Ownership to learn about the owners and their transactions.
- TERNS PHARMACEUTICALS INC (TERN) Stock Chart to make your own analysis
- TERNS PHARMACEUTICALS INC (TERN) Latest news and press-releases to stay up to date.
Does TERNS PHARMACEUTICALS INC (TERN) stock pay dividends?
TERN does not pay a dividend.
When does TERNS PHARMACEUTICALS INC (TERN) report earnings?
TERNS PHARMACEUTICALS INC (TERN) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of TERNS PHARMACEUTICALS INC (TERN)?
TERNS PHARMACEUTICALS INC (TERN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).
What is the Short Interest ratio of TERNS PHARMACEUTICALS INC (TERN) stock?
The outstanding short interest for TERNS PHARMACEUTICALS INC (TERN) is 6.8% of its float. Check the ownership tab for more information on the TERN short interest.
TERN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TERN. When comparing the yearly performance of all stocks, TERN is a bad performer in the overall market: 88.97% of all stocks are doing better.
TERN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TERN. While TERN has a great health rating, there are worries on its profitability.
TERN Financial Highlights
Over the last trailing twelve months TERN reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 13.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.41% | ||
| ROE | -25.69% | ||
| Debt/Equity | 0 |
TERN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to TERN. The Buy consensus is the average rating of analysts ratings from 16 analysts.